Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating Expenses:    
Research And Development $ 1,677,932 $ 1,206,779
General And Administrative 779,254 687,936
Total Operating Expenses 2,457,186 1,894,715
Loss From Operations (2,457,186) (1,894,715)
Other Income:    
Interest Income 464 10,696
Net Loss (2,456,722) (1,884,019)
Other Comprehensive Income (loss):    
Foreign Currency Translation Gain (loss) (584) 2,774
Comprehensive Loss $ (2,457,306) $ (1,881,245)
Net Loss Per Share:    
Basic And Diluted $ (0.19) $ (0.16)
Weighted Average Shares Outstanding:    
Basic And Diluted 12,604,443 12,139,422